Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin’s lymphoma.
1. What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin’s lymphoma? (0:10)
2. Could you tell us a little about the ECHELON-1 study and its findings? (1:04)
3. What toxicities were associated with the A+AVD regimen? (2:11)
4. What patients are most likely to respond to this approach? (4:46)
5. What future studies are planned? (6:05)
Speaker disclosures: Martin Hutchings has nothing to disclose in relation to this video interview.
Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018
A+AVD = brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine
Share this Video
Related Videos In Lymphoma
Manali Kamdar, ASH 2021: Results from the Randomized Phase III TRANSFORM Study
We were delighted to catch up with Dr Manali Kamdar (University of Colorado, Boulder, CO, USA) to discuss the results of the randomized phase III TRANSFORM study of lisocabtagene maraleucel CAR-T cell therapy versus standard of care chemotherapy followed by ASCT in patients with relapsed or refractory large b-cell lymphoma. Question Please can you summarise […]
Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma
At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma. Questions 1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05) 2. What is the role of brentuximab vedotin in the current […]
Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 Study
We are joined by Andrea Gallamini, at EHA 2019 to discuss his presentation on frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Questions 1. Could you tell us a little about the ECHELON-1 study and its findings? (0:05) 2. What have we learned from the 3-year […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!